Research Article
Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution
Table 3
Association of EZH2 gene expression with clinical features, karyotypes and leukemic evolution in pediatric patients with primary MDS.
| Parameter | EZH2 gene expression (median) | value |
| Age of patients | < 12 years old (children), | 1.8 | | > 12 years old (adolescents), | 2.7 | Pediatric patients () | 1.8 | | Pediatric healthy individuals () | 1.15 | MDS subtypes | Initial stage (RCC) () | 1.7 | | Advanced stages (RAEB/RAEB-t) () | 2.9 | Karyotypes | Normal () | 1.7 | | Abnormal () | 1.8 | Specific chromosomal pattern | Normal karyotypes () | 1.7 | | −7 and del(7q) () | 0.2 | +8 () | 5.96 | del(11q) () | 6.35 | Levels of EZH2 expression | Low () | 0.2 | | Intermediate () | 1.61 | High () | 4.81 |
| Donors versus levels of EZH2 expression (groups) | Donors | Groups | | Donors () vs. Low expression patients () | 1.15 | 0.2 | | Donors () vs. Intermediate expression patients () | 1.15 | 1.61 | | Donors () vs. High expression patients () | 1.15 | 4.81 | | | Low (8/8) | | Evolution of disease (MDS →AML) versus levels of EZH2 expression | Intermediate (1/23) | | High (7/11) | Evolution of disease (MDS →AML) versus levels of EZH2 expression | Low (8/8) | | High (7/11) |
|
|